Clinical Trials Directory

Trials / Completed

CompletedNCT01012531

Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen

Efficacy and Safety of Subcutaneous Cluster Immunotherapy With Cluster-allergoid CLUSTOID Grasses/Rye (Glutaraldehyde-polymerized Allergen Extract of Mixtures of Grass and Rye Allergens) in Patients With Allergic Rhinoconjunctivitis Sensitized to Grass and With or Without Rye Pollen Sensitization

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
121 (actual)
Sponsor
Roxall Medizin · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to assess the efficacy and safety of cluster immunotherapy with highly polymerized allergen extracts.

Conditions

Interventions

TypeNameDescription
BIOLOGICALSubcutaneous injections with highly polymerized allergen extractcluster schedule
BIOLOGICALSubcutaneous injection with placebocluster schedule

Timeline

Start date
2008-10-01
Primary completion
2009-11-01
Completion
2009-12-01
First posted
2009-11-13
Last updated
2011-07-14

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01012531. Inclusion in this directory is not an endorsement.

Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen (NCT01012531) · Clinical Trials Directory